Treatment of 63 Subjects With Digital Mucous Cysts With Percutaneous Sclerotherapy Using Polidocanol

Dermatol Surg. 2016 Jan;42(1):59-62. doi: 10.1097/DSS.0000000000000601.

Abstract

Background: Digital mucous cysts (digital myxoid cysts or DMCs) are benign cystic swellings typically affecting the digital distal interphalangeal joint or the proximal nail fold. Many treatment modalities exist; however, permanent scarring, wound infection, and recurrence are common. Polidocanol sclerotherapy has been reported as a potential treatment.

Objective: To assess the efficacy and safety of percutaneous polidocanol sclerotherapy in the treatment of DMC.

Materials and methods: The authors performed polidocanol sclerotherapy in 63 patients (23 men and 40 women). For each patient, the DMC contents were extruded and 3% polidocanol (0.02-0.5 mL) was injected to gently refill the cyst to its previous size. Subjects were reviewed after 6 weeks and offered a second treatment if necessary, and reviewed again after 12 weeks. Changes in lesions and adverse reactions were noted.

Results: Of the 63 subjects treated, 43 (68.3%) experienced complete resolution of the cyst by 6 weeks, and 49 (77.8%) experienced complete resolution by 12 weeks. Side effects were minor and had resolved in all patients by 12-week review.

Conclusion: Percutaneous polidocanol sclerotherapy is a simple, safe, and effective approach to treating DMC, and is suitable for office-based practice.

MeSH terms

  • Administration, Cutaneous
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Fingers
  • Ganglion Cysts / therapy*
  • Humans
  • Male
  • Middle Aged
  • Polidocanol
  • Polyethylene Glycols / administration & dosage*
  • Sclerosing Solutions / administration & dosage*
  • Sclerotherapy / methods*
  • Treatment Outcome
  • Young Adult

Substances

  • Sclerosing Solutions
  • Polidocanol
  • Polyethylene Glycols